Drugs

CA Man Pleads Guilty to Selling Unapproved Drugs

A California man operating a company called Warrior Labz SARMs has pleaded guilty to selling unapproved drugs. According to the Justice Department, Jeremy Brown sold selective androgen receptor modulators, unapproved versions of erectile-dysfunction drugs Viagra and Cialis; and unapproved versions of weight-loss drugs Ozempic, Wegovy, and Rybelsus from 2019 to 2023.

“Brown falsely claimed on his websites that the drugs offered for sale were for ‘research purposes only’ and ‘not for human consumption,’” the government contends. “Alongside those claims, however, were claims that the drugs would provide various benefits affecting the structure and function of the human body.”

It is said that Brown obtained the bulk of the drugs he sold from China. “Brown did not verify shipping or storage conditions, nor did he use a lab to verify the contents of the drugs he received from China,” the government says. “But he falsely claimed on his Web sites that his company used only the highest quality pharmaceutical grade ingredients and U.S. manufacturing practices.”

After receiving an FDA Warning Letter 6/2023, Brown continued to sell unapproved drugs over the internet, including three sales of unapproved drugs to an undercover law enforcement account, the government says.

Brown faces up to three years in prison and a $250,000 fine.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome